T‐Cell Lymphoproliferative Disorders

Matutes, Estella

doi:10.1002/9781444323160.ch30

Cited by 2 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mutations in any of the TCR subunits lead to T‐lymphoproliferative diseases derived from post‐thymic immunocompetent lymphoid cells such as in T‐PLL (26). There is no evidence that radiation, carcinogenic agents or viruses play a role in the pathogenesis of T‐PLL (27). In adults T‐PLL arises sporadically and there is a close relationship between the sporadic form of T‐PLL and the leukaemia that occurs in patients with the inherited disorder ataxia telengectasia (AT) (28).…”

Section: T‐cell Prolymphocytic Leukaemiamentioning

confidence: 99%

See 1 more Smart Citation

Prolymphocytic leukaemia of B‐ and T‐cell subtype: a state‐of‐the‐art paper

Dungarwalla¹,

Matutes²,

Dearden³

2008

European J of Haematology

View full text Add to dashboard Cite

Prolymphocytic leukaemias of B and T cell subtype are rare diseases. Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor. Purine analogues and monoclonal antibodies have shown efficacy in B‐cell prolymphocytic leukaemia although further studies are warranted. Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T‐cell prolymphocytic leukaemia (T‐PLL) but responses are still transient and further disease progression is inevitable. While allogeneic stem cell transplant is an attractive option, due to the older age group of T‐PLL patients the morbidity and mortality associated with the procedure is significant.

show abstract

Section: T‐cell Prolymphocytic Leukaemiamentioning

confidence: 99%

“…In the remaining cases the prolymphocytes are smaller in size or have a cerebriform nucleus resembling Sezary syndrome, and have a small nucleolus which may not be visible on light microscopy. Both morphological variants have an aggressive disease course with similar immunophenotype and cytogenetics (27).…”

Section: T‐cell Prolymphocytic Leukaemiamentioning

confidence: 99%

Prolymphocytic leukaemia of B‐ and T‐cell subtype: a state‐of‐the‐art paper

Dungarwalla¹,

Matutes²,

Dearden³

2008

European J of Haematology

View full text Add to dashboard Cite

show abstract

Use of thiopurines in inflammatory bowel disease: Safety issues

Konidari¹,

El‐Matary²

2014

WJGPT

View full text Add to dashboard Cite

Thiopurines are widely used for maintenance treatment of inflammatory bowel disease. Inter-individual variability in clinical response to thiopurines may be attributed to several factors including genetic polymorphisms, severity and chronicity of disease, comorbidities, duration of administration, compliance issues and use of concomitant medication, environmental factors and clinician and patient preferences. The purpose of this review is to summarise the current evidence on thiopurine safety and toxicity, to describe adverse drug events and emphasise the significance of drug interactions, and to discuss the relative safety of thiopurine use in adults, elderly patients, children and pregnant women. Thiopurines are safe to use and well tolerated, however dose adjustment or discontinuation of treatment must be considered in cases of non-response, poor compliance or toxicity. Drug safety, clinical response to treatment and short to long term risks and benefits must be balanced throughout treatment duration for different categories of patients. Treatment should be individualised and stratified according to patient requirements. Enzymatic testing prior to treatment commencement is advised. Surveillance with regular clinic follow-up and monitoring of laboratory markers is important. Data on long term efficacy, safety of thiopurine use and interaction with other disease modifying drugs are lacking, especially in paediatric inflammatory bowel disease. High quality, collaborative clinical research is required so as to inform clinical practice in the future.

show abstract

T‐Cell Lymphoproliferative Disorders

Cited by 2 publications

References 29 publications

Prolymphocytic leukaemia of B‐ and T‐cell subtype: a state‐of‐the‐art paper

Prolymphocytic leukaemia of B‐ and T‐cell subtype: a state‐of‐the‐art paper

Use of thiopurines in inflammatory bowel disease: Safety issues

Contact Info

Product

Resources

About